Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference

2 hours ago 2

MarketBeat

Tue, March 3, 2026 astatine 2:29 AM CST 7 min read

Anika Therapeutics logo

Anika reported positive EBITDA and escaped currency travel successful 2025 (about $5M adjusted EBITDA and >$11M operating currency flow), with much than $50M successful currency and nary indebtedness supporting its equilibrium sheet.
Management frames a >$3 cardinal TAM led by >$1B opportunities for Hyalofast and Cingal; Cingal is advancing toward a U.S. NDA (toxicity studies complete, bioequivalence survey underway) portion Hyalofast’s PMA remains successful progressive reappraisal aft mixed primary/secondary endpoint results.
Revenue premix is bifurcated: the OEM transmission (Monovisc/Orthovisc via J&J) faces U.S. pricing unit and whitethorn beryllium flat-to-modestly little successful 2026, portion the commercialized transmission is increasing successful the mid-teens with 2026 guidance of 10–20% maturation and company-wide adjusted EBITDA expected astatine 5–10% of revenue.
Interested successful Anika Therapeutics Inc.? Here are 5 stocks we similar better.

Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company’s strategy, merchandise portfolio, and maturation priorities during a presumption astatine the Canaccord Genuity Musculoskeletal Conference, emphasizing a absorption connected top-line growth, a differentiated hyaluronic acid-based exertion platform, and continued concern successful its pipeline.

Griffin said Anika has operated for 33 years with a superior absorption connected hyaluronic acerb (HA) technologies spanning osteoarthritis (OA) symptom absorption and regenerative medicine. He described the concern arsenic generating “strong profitability” and “strong currency flow,” supported by a equilibrium expanse with much than $50 cardinal successful currency and nary debt.

→ The Head Fake: Buying the Chinese Stocks Post-Ruling Dip

Griffin besides referenced caller results, stating the institution “just announced” its results past week, including affirmative EBITDA and affirmative escaped currency travel successful 2025. He said Anika generated astir $5 cardinal of adjusted EBITDA and much than $11 cardinal of operating currency travel successful 2025.

Anika’s concern is organized into 2 superior portfolios:

OA Pain Management: Orthovisc, Monovisc, and Cingal (viscosupplement injection products)
Regenerative Solutions: Integrity and Hyalofast (built connected the company’s HYAFF technology)

→ MarketBeat Week successful Review – 02/23 - 02/27

Griffin framed the company’s wide accidental acceptable arsenic a full addressable marketplace (TAM) of much than $3 billion, and provided TAM estimates for respective categories:

Monovisc and Orthovisc: much than $1 cardinal TAM
Integrity Implant System: astir $230 cardinal TAM successful the U.S. (Griffin besides referenced “about a $200 million” accidental successful discussing the product)
Hyalofast (U.S. opportunity): much than $1 cardinal TAM
Cingal: different $1 cardinal of TAM potential, which Griffin characterized arsenic a next-generation OA symptom absorption product